COL1A1 and metabolic dysfunction-associated steatotic liver disease: Although the histopathological findings in our study did not show significant alterations in hepatic inflammation and fibrosis, diminished levels of Col1a1 and Saa1 mRNAs suggest a potential role of genistein treatment in slowing MASLD progression.